Evidence map›Paper›PMID 42667446›Full record

ArticleMolecular biology reports2026

Cyclofenil blocks the secretion of IL-1β by inhibiting assembly of the NLRP3 inflammasome independent of estrogen receptor.

Jieqiong Feng, Youyou Yan, Jiafeng Liang, Yanyan Zhao, Jingjing Zhang, Jian Xu, Shenglin Ma, Shirong Zhang, Shujun Xie

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jieqiong Feng *Department of Pathology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, 310006, China.
Youyou Yan *Department of Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, 310006, China.
Jiafeng Liang *Department of Thoracic Oncology, Hangzhou Cancer Hospital, Hangzhou, 310006, China.
Yanyan ZhaoDepartment of Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, 310006, China.
Jingjing ZhangDepartment of Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, 310006, China.
Jian XuDepartment of Clinical Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.
Shenglin MaDepartment of Oncology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, 310006, China.
Shirong ZhangDepartment of Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province Hangzhou, Affiliated Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Shujun XieDepartment of Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, 310006, China. xieshujun@zju.edu.cn.ORCID https://orcid.org/0000-0002-1582-9175

Funding

Construction Fund of Key Medical Disciplines of Hangzhou 2025HZGF06Hangzhou Joint Fund of Zhejiang Provincial Natural Science Foundation of China HZQN26H160003Medical and Health Technology Plan of Zhejiang Province 2022KY978National Natural Science Foundation of China 82003017National Natural Science Foundation of China 82103787Zhejiang Provincial Natural Science Foundation of China LQ20H310004Zhejiang Provincial Natural Science Foundation of China LTGY24H160025
6 · The paper itself

Abstract

Cyclofenil is a modulator of estrogen receptor and is used clinically as an ovulation-inducing drug with antiviral activity. However, the mechanism by which cyclofenil works without estrogen receptor remains unknown. In this study, we screened for a small-molecule drug targeting the NLRP3 inflammasome and found that cyclofenil inhibited the secretion of IL-1β in a dose-dependent manner. Intriguingly, cyclofenil impedes activation of the NLRP3 inflammasome, independent of estrogen receptor, without interfering with the priming stage. Additionally, cyclofenil blocks ASC oligomerization and pyroptosis, preventing maturation of IL-1β and caspase-1. This study offers new evidence that cyclofenil is an anti-inflammatory drug and may be a novel clinical option for NLRP3 inflammasome-related diseases.

Indexed as

InflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsAnti-Inflammatory AgentsCaspase 1HumansMiceReceptors, EstrogenAnti-Inflammatory AgentsCaspase 1InflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseReceptors, EstrogenCyclofenilEstrogen receptorInflammasomeInflammationNLRP3

Identifiers

PMID42667446

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.